203 related articles for article (PubMed ID: 25324682)
1. Apelin in epiretinal membranes of patients with proliferative diabetic retinopathy.
Lu Q; Ma Y; Xu YS; Jiang YR
Mol Vis; 2014; 20():1122-31. PubMed ID: 25324682
[TBL] [Abstract][Full Text] [Related]
2. Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab.
Zhang Y; Jiang YR; Lu Q; Yin H; Tao Y
Retina; 2013 Mar; 33(3):613-20. PubMed ID: 23296045
[TBL] [Abstract][Full Text] [Related]
3. Expression of wild-type p53-induced phosphatase 1 in diabetic epiretinal membranes.
Xu J; Zhong H; Cui L; Lan Q; Chen L; He W; Wu Y; Jiang L; Huang H; Zhao X; Li L; Zeng S; Li M; Xu F
Oncotarget; 2017 May; 8(22):35532-35541. PubMed ID: 28402943
[TBL] [Abstract][Full Text] [Related]
4. Diverse NF-kappaB expression in epiretinal membranes after human diabetic retinopathy and proliferative vitreoretinopathy.
Harada C; Harada T; Mitamura Y; Quah HM; Ohtsuka K; Kotake S; Ohno S; Wada K; Takeuchi S; Tanaka K
Mol Vis; 2004 Jan; 10():31-6. PubMed ID: 14737065
[TBL] [Abstract][Full Text] [Related]
5. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
6. NF-kappaB in epiretinal membranes after human diabetic retinopathy.
Mitamura Y; Harada T; Harada C; Ohtsuka K; Kotake S; Ohno S; Tanaka K; Takeuchi S; Wada K
Diabetologia; 2003 May; 46(5):699-703. PubMed ID: 12743697
[TBL] [Abstract][Full Text] [Related]
7. Extracellular matrix proteins in epiretinal membranes and in diabetic retinopathy.
George B; Chen S; Chaudhary V; Gonder J; Chakrabarti S
Curr Eye Res; 2009 Feb; 34(2):134-44. PubMed ID: 19219685
[TBL] [Abstract][Full Text] [Related]
8. Neurotrophic factor receptors in epiretinal membranes after human diabetic retinopathy.
Harada T; Harada C; Mitamura Y; Akazawa C; Ohtsuka K; Ohno S; Takeuchi S; Wada K
Diabetes Care; 2002 Jun; 25(6):1060-5. PubMed ID: 12032115
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes.
Tsanou E; Ioachim E; Stefaniotou M; Gorezis S; Charalabopoulos K; Bagli H; Peschos D; Psilas K; Agnantis NJ
Int J Clin Pract; 2005 Oct; 59(10):1157-61. PubMed ID: 16178982
[TBL] [Abstract][Full Text] [Related]
10. Tenascin-C promotes angiogenesis in fibrovascular membranes in eyes with proliferative diabetic retinopathy.
Kobayashi Y; Yoshida S; Zhou Y; Nakama T; Ishikawa K; Arima M; Nakao S; Sassa Y; Takeda A; Hisatomi T; Ikeda Y; Matsuda A; Sonoda KH; Ishibashi T
Mol Vis; 2016; 22():436-45. PubMed ID: 27186070
[TBL] [Abstract][Full Text] [Related]
11. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
[TBL] [Abstract][Full Text] [Related]
12. Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients.
Feng J; Li B; Wen J; Jiang Y
Ophthalmic Res; 2018; 60(4):250-257. PubMed ID: 30380554
[TBL] [Abstract][Full Text] [Related]
13. Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α.
Han XX; Guo CM; Li Y; Hui YN
Mol Vis; 2012; 18():1-9. PubMed ID: 22232563
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactive endothelin-1 in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy.
Roldán-Pallarés M; Rollín R; Martínez-Montero JC; Fernández-Cruz A; Bravo-Llata C; Fernández-Durango R
Retina; 2007 Feb; 27(2):222-35. PubMed ID: 17290206
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of RAGE and its ligands in proliferative retinal disease.
Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study of extracellular matrix components in epiretinal membranes of vitreoproliferative retinopathy and proliferative diabetic retinopathy.
Ioachim E; Stefaniotou M; Gorezis S; Tsanou E; Psilas K; Agnantis NJ
Eur J Ophthalmol; 2005; 15(3):384-91. PubMed ID: 15945009
[TBL] [Abstract][Full Text] [Related]
17. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor.
Abu El-Asrar AM; Nawaz MI; De Hertogh G; Al-Kharashi AS; Van den Eynde K; Mohammad G; Geboes K
Curr Eye Res; 2015 Mar; 40(3):321-31. PubMed ID: 24871583
[TBL] [Abstract][Full Text] [Related]
18. Cysteine-rich 61 (CYR61) is up-regulated in proliferative diabetic retinopathy.
Zhang X; Yu W; Dong F
Graefes Arch Clin Exp Ophthalmol; 2012 May; 250(5):661-8. PubMed ID: 22160564
[TBL] [Abstract][Full Text] [Related]
19. Atrial natriuretic peptide in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy.
Rollin R; Mediero A; Martínez-Montero JC; Roldán-Pallarés M; Suárez-Leoz M; Vidal-Fernández P; Cortés-Valdés C; Fernández-Cruz A; Fernández-Durango R
Mol Vis; 2004 Jul; 10():450-7. PubMed ID: 15273657
[TBL] [Abstract][Full Text] [Related]
20. Apelin in plasma and vitreous and in fibrovascular retinal membranes of patients with proliferative diabetic retinopathy.
Tao Y; Lu Q; Jiang YR; Qian J; Wang JY; Gao L; Jonas JB
Invest Ophthalmol Vis Sci; 2010 Aug; 51(8):4237-42. PubMed ID: 20220056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
